Page 1081 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1046 ParT EighT Immunology of Neoplasia

(anti-CTLA-4) is being tested in patients with metastatic mela- 16. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine
noma and lung, breast, and pancreatic cancer (ClinicalTrials. for previously untreated metastatic melanoma. N Engl J Med
gov). 2011;364(26):2517–26.
17. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab
versus placebo after complete resection of high-risk stage III melanoma
CONCLUSIONS (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet
Oncol 2015;16(5):522–30.
Cancer immunotherapy has established itself as a critical pillar 18. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term
in cancer therapy. It has resulted in durable clinical responses Survival Data From Phase II and Phase III Trials of Ipilimumab in
in patients whose tumors were refractory to conventional Unresectable or Metastatic Melanoma. J Clin Oncol
anticancer therapies. Nonetheless, additional research is required 2015;33(17):1889–94.
to further optimize the existing immunotherapeutic approaches 19. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy
and also to assess new strategies in this emerging field with in patients with advanced melanoma who progressed after anti-CTLA-4
significant untapped potential. Current challenges include rational treatment (CheckMate 037): a randomised, controlled, open-label, phase
development and optimization of combination strategies, 3 trial. Lancet Oncol 2015;16(4):375–84.
identification of biomarkers, and continued support for basic 20. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated
melanoma without BRAF mutation. NEJM 2015;372(4):320–30.
and translational research to provide a greater understanding 21. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus
of mechanisms that drive antitumor immune response. Cancer investigator-choice chemotherapy for ipilimumab-refractory melanoma
immunotherapy has made great strides in improving clinical (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol
outcomes for some patients, and there is great hope that continued 2015;16(8):908–18.
research efforts will enable even more patients to benefit in the 22. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus
future. Ipilimumab in Advanced Melanoma. N Engl J Med
2015;372(26):2521–32.
Please check your eBook at https://expertconsult.inkling.com/ 23. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and
for self-assessment questions. See inside cover for registration Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med
details. 2015;373(1):23–34.
24. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational
processes in human cancer. Nature 2013;500(7463):415–21.
REFERENCES 25. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in
advanced squamous-cell non–small-cell lung cancer. NEJM
1. Nauts HC. Bacterial pyrogens: beneficial effects on cancer patients. 2015;373(2):123–35.
Prog Clin Biol Res 1982;107:687–96. 26. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in
2. Bassi P. BCG (Bacillus of Calmette Guerin) therapy of high-risk Advanced Nonsquamous Non–Small-Cell Lung Cancer. NEJM
superficial bladder cancer. Surg Oncol 2002;11(1-2):77–83. 2015;373(17):1627–39.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating 27. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for
immunity’s roles in cancer suppression and promotion. Science previously treated, PD-L1-positive, advanced non-small-cell lung cancer
2011;331(6024):1565–70. (KEYNOTE-010): a randomised controlled trial. Lancet
4. Quail DF, Joyce JA. Microenvironmental regulation of tumor 2016;387(10027):1540–50.
progression and metastasis. Nat Med 2013;19(11):1423–37. 28. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus
5. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. chemotherapy for PD-L1-Positive non-small-cell lung cancer. N Engl J
Annu Rev Immunol 2004;22:329–60. Med 2016;375(19):1823–33.
6. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a 29. Liu XD, Hoang A, Zhou L, et al. Resistance to antiangiogenic therapy is
negative regulator of T cell activation. Immunity 1994;1(5):405–13. associated with an immunosuppressive tumor microenvironment in
7. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on metastatic renal cell carcinoma. Cancer Immunol Res
the response of T cells to stimulation. J Exp Med 1995;182(2):459–65. 2015;3(9):1017–29.
8. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor 30. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus
immunity by CTLA-4 blockade. Science 1996;271(5256):1734–6. everolimus in advanced renal-cell carcinoma. NEJM
9. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;373(19):1803–13.
2015;348(6230):56–61. 31. Shi LZ, Fu T, Guan B, et al. Interdependent IL-7 and IFN-gamma
10. Sharma P, Wagner K, Wolchok JD, et al. Novel cancer immunotherapy signalling in T-cell controls tumour eradication by combined
agents with survival benefit: recent successes and next steps. Nat Rev alpha-CTLA-4+alpha-PD-1 therapy. Nat Commun 2016;7:12335.
Cancer 2011;11(11):805–12. 32. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in
11. Hamanishi J, Mandai M, Matsumura N, et al. PD-1/PD-L1 blockade in patients with locally advanced and metastatic urothelial carcinoma who
cancer treatment: perspectives and issues. Int J Clin Oncol have progressed following treatment with platinum-based
2016;21(3):462–73. chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet
12. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 2016;387(10031):1909–20.
pathways to reverse T cell exhaustion and restore anti-tumor immunity. 33. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in
J Exp Med 2010;207(10):2187–94. recurrent metastatic urothelial carcinoma (CheckMate 032): a
13. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet
cells. Immunity 2004;21(4):503–13. Oncol 2016;17(11):1590–8.
14. Wang L, Rubinstein R, Lines JL, et al. VISTA, a novel mouse Ig 34. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic
superfamily ligand that negatively regulates T cell responses. J Exp Med urothelial carcinoma after platinum therapy (CheckMate 275): a
2011;208(3):577–92. multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):
15. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with 312–22.
ipilimumab in patients with metastatic melanoma. NEJM 35. Sharma P, Callahan MK, Calvo E, et al. Efficacy and safety of nivolumab
2010;363(8):711–23. plus ipilimumab in previously treated metastatic urothelial carcinoma: